We are a late-stage biotech company focused on addressing diseases of the central nervous system (CNS).

Our most advanced program is REL-1017, a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels associated with major depressive disorder (MDD), while maintaining physiological glutamatergic neurotransmission. We believe that REL-1017 has the potential to transform the current neuropharmacological approach to MDD, and we are rapidly advancing toward investigating REL-1017 for potential indications as adjunctive and monotherapy.

Depression represents the largest cause of disability around the world¹. Our dedicated team is focused on moving REL-1017 forward as a potentially transformational option for people living with MDD.

Based on our Phase 1 and Phase 2 studies, we believe there is a real potential for REL-1017 to treat MDD safely, effectively, and more quickly than is currently possible with a well-tolerated, oral, once-daily tablet. REL-1017 received Fast Track Designation and has entered the pivotal Phase 3 programs with studies as an adjunctive treatment in adults. REL-1017 has also initiated a Phase 3 study for monotherapy.

We are growing our company accordingly as we execute our Phase 3 program: Reliance I, Reliance II, Reliance III, and Reliance-OLS for REL-1017. We have assembled an experienced development team to advance this promising program.